Clinical trial
Phase 2, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Patients With Locally Advanced Unresectable or Metastatic Esophageal Squamous Cell Carcinoma That Progressed on or After Anti-PD-(L)1 Antibody Therapy
NCT05461794 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Patients With Locally Advanced Unresectable or Metastatic Esophageal Squamous Cell Carcinoma That Progressed on or After Anti-PD-(L)1 Antibody Therapy
- Lead sponsor
- BeiGene
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 3, 2022
- Completion date
- February 26, 2024
- Enrollment
- 96 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.